ReviewInternational journal of molecular sciences2021
Hypothyroidism-Associated Dyslipidemia: Potential Molecular Mechanisms Leading to NAFLD.
Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07236697 (Impact of Subclinical Hypothyroidism on Liver Enzymes and Lipid Profile), which is not on this map. Cited by 82 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Impact of Subclinical Hypothyroidism on Liver Enzymes and Lipid Profile
Who cites it
82 citing papers in PubMed, 4 syntheses or guidelines pooled it, 121 citations in OpenAlex.
- Association between maternal thyroid function and adverse outcomes of pregnant women and offspring: evidence from an umbrella review.BMC pregnancy and childbirth · 2026Pooled it
- Pooled it
- Evidence on the link between hypothyroidism and non-alcoholic fatty liver disease: an updated systematic review.BMC endocrine disorders · 2025Pooled it
- Pooled it
- Dyslipidemias associated with endocrine disorders: a position statement of the working group of the nutrition hormones and metabolism club of the italian society of endocrinology (SIE).Journal of endocrinological investigation · 2026Review
- The association between T4 and TSH with lipid profile is attenuated in patients with established dyslipidemia.BMC endocrine disorders · 2026Article
- Effectiveness of nutrition education program and omega-3 supplementation on body weight, liver enzyme, lipid profile among non-alcoholic fatty liver disease patients.BMC nutrition · 2026Article
- Thyroid dysfunction and its association with micronutrients, lipids, and inflammation: an analytical case-control study.BMC endocrine disorders · 2026Observational
- Associations of Multimarkers of Metabolic Malnutrition and Inflammation With All-Cause Mortality and Their Interplay With Thyroid Function.Endocrinology, diabetes & metabolism · 2026Article
- Thyroid hormone replacement is associated with improvement in renal dysfunction in patients with hypothyroidism: a retrospective observational study.Frontiers in endocrinology · 2026Observational
- Correlation Between the Thyroid Hormone Levels and Type 2 Diabetes Mellitus in Non-Alcoholic Fatty Liver Disease.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Article
- Age-related changes in HPT axis sensitivity and their associations with metabolic and cardiovascular health: a cross-sectional, Chinese nationwide study.Frontiers in endocrinology · 2026Article
- A Rare Presentation of Myxedema Coma Complicated by Acute Coronary Syndrome Successfully Managed With Oral Levothyroxine.JCEM case reports · 2026Article
- Long-term metabolic risks after thyroidectomy and thyroid hormone therapy in thyroid cancer survivors: a nationwide cohort study.Frontiers in endocrinology · 2026Article
- Review
- Integrating Thyroid Function with Body Composition: The BRITSH Ratio and Cardiovascular Risk - A Pilot Study.Anatolian journal of cardiology · 2025Article
- Association of thyroid function and thyroid hormone sensitivity with all-cause and cardiovascular mortality in euthyroid patients with MASLD.Clinical and experimental hepatology · 2025Article
- Modulation of metabolic syndrome components by oral semaglutide in hypothyroid-T2DM patients: a retrospective analysis.Journal of medicine and life · 2025Article
- From mechanisms to management: Early detection and improved treatment of MASLD and its related hepatocellular carcinoma.Hepatology communications · 2025Review
- Resmetirom, the first FDA-approved drug for MASH: From drug discovery and action mechanisms to clinical trials.Archives of pharmacal research · 2025Review
22 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thyroid hormones control lipid metabolism by exhibiting specific effects on the liver and adipose tissue in a coordinated manner. Different diseases of the thyroid gland can result in hypothyroidism. Hypothyroidism is frequently associated with dyslipidemia. Hypothyroidism-associated dyslipidemia subsequently results in intrahepatic accumulation of fat, leading to nonalcoholic fatty liver disease (NAFLD), which leads to the development of hepatic insulin resistance. The prevalence of NAFLD in the western world is increasing, and evidence of its association with hypothyroidism is accumulating. Since hypothyroidism has been identified as a modifiable risk factor of NAFLD and recent data provides evidence that selective thyroid hormone receptor β (THR-β) agonists are effective in the treatment of dyslipidemia and NAFLD, interest in potential therapeutic options for NAFLD targeting these receptors is growing. In this review, we summarize current knowledge regarding clinical and molecular data exploring the association of hypothyroidism, dyslipidemia and NAFLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.